tetano
Editor, Senior Moderator
PLoS Pathog
. 2024 Apr 1;20(4):e1012116.
doi: 10.1371/journal.ppat.1012116. Online ahead of print. Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex
Pei Du[SUP] 1 [/SUP], Lei Huang[SUP] 2 [/SUP], Yi Fang[SUP] 2 [/SUP], Fanfan Zhao[SUP] 2 [/SUP], Qianyun Li[SUP] 2 [/SUP], Xuehui Ma[SUP] 1 [/SUP], Ruiqi Li[SUP] 1 3 [/SUP], Qian Chen[SUP] 1 4 [/SUP], Haifa Shen[SUP] 2 [/SUP], Qihui Wang[SUP] 1 3 4 [/SUP], Hangwen Li[SUP] 2 [/SUP], George Fu Gao[SUP] 1 3 4 [/SUP]
Affiliations
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, continues to mutate and generates new variants with increasingly severe immune escape, urging the upgrade of COVID-19 vaccines. Here, based on a similar dimeric RBD design as our previous ZF2001 vaccine, we developed a novel broad-spectrum COVID-19 mRNA vaccine, SWIM516, with chimeric Delta-BA.2 RBD dimer delivered by lipopolyplex (LPP). Unlike the popular lipid nanoparticle (LNP), this LPP-delivered mRNA expresses only in the injection site, which avoids potential toxicity to the liver. We demonstrated the broad-spectrum humoral and cellular immunogenicity of this vaccine to Delta and Omicron sub-variants in naïve mice and as booster shots. When challenged with Delta or Omicron live virus, vaccinated hACE2 transgenic mice and rhesus macaques were both protected, displaying significantly reduced viral loads and markedly relieved pathological damages. We believe the SWIM516 vaccine qualifies as a candidate for the next-generation broad-spectrum COVID-19 vaccine.
. 2024 Apr 1;20(4):e1012116.
doi: 10.1371/journal.ppat.1012116. Online ahead of print. Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex
Pei Du[SUP] 1 [/SUP], Lei Huang[SUP] 2 [/SUP], Yi Fang[SUP] 2 [/SUP], Fanfan Zhao[SUP] 2 [/SUP], Qianyun Li[SUP] 2 [/SUP], Xuehui Ma[SUP] 1 [/SUP], Ruiqi Li[SUP] 1 3 [/SUP], Qian Chen[SUP] 1 4 [/SUP], Haifa Shen[SUP] 2 [/SUP], Qihui Wang[SUP] 1 3 4 [/SUP], Hangwen Li[SUP] 2 [/SUP], George Fu Gao[SUP] 1 3 4 [/SUP]
Affiliations
- PMID: 38557908
- DOI: 10.1371/journal.ppat.1012116
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, continues to mutate and generates new variants with increasingly severe immune escape, urging the upgrade of COVID-19 vaccines. Here, based on a similar dimeric RBD design as our previous ZF2001 vaccine, we developed a novel broad-spectrum COVID-19 mRNA vaccine, SWIM516, with chimeric Delta-BA.2 RBD dimer delivered by lipopolyplex (LPP). Unlike the popular lipid nanoparticle (LNP), this LPP-delivered mRNA expresses only in the injection site, which avoids potential toxicity to the liver. We demonstrated the broad-spectrum humoral and cellular immunogenicity of this vaccine to Delta and Omicron sub-variants in naïve mice and as booster shots. When challenged with Delta or Omicron live virus, vaccinated hACE2 transgenic mice and rhesus macaques were both protected, displaying significantly reduced viral loads and markedly relieved pathological damages. We believe the SWIM516 vaccine qualifies as a candidate for the next-generation broad-spectrum COVID-19 vaccine.